153 related articles for article (PubMed ID: 29928505)
21. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
Kresoja-Rakic J; Kapaklikaya E; Ziltener G; Dalcher D; Santoro R; Christensen BC; Johnson KC; Schwaller B; Weder W; Stahel RA; Felley-Bosco E
Oncotarget; 2016 Apr; 7(16):21272-86. PubMed ID: 26848772
[TBL] [Abstract][Full Text] [Related]
22. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
Bianchi AB; Mitsunaga SI; Cheng JQ; Klein WM; Jhanwar SC; Seizinger B; Kley N; Klein-Szanto AJ; Testa JR
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10854-8. PubMed ID: 7479897
[TBL] [Abstract][Full Text] [Related]
23. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent.
Robinson C; van Bruggen I; Segal A; Dunham M; Sherwood A; Koentgen F; Robinson BW; Lake RA
Cancer Res; 2006 Nov; 66(22):10786-94. PubMed ID: 17108115
[TBL] [Abstract][Full Text] [Related]
24. Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
Kresoja-Rakic J; Sulemani M; Kirschner MB; Ronner M; Reid G; Kao S; Schwaller B; Weder W; Stahel RA; Felley-Bosco E
Front Genet; 2017; 8():70. PubMed ID: 28611824
[TBL] [Abstract][Full Text] [Related]
25. Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas.
Goodglick LA; Vaslet CA; Messier NJ; Kane AB
Toxicol Pathol; 1997; 25(6):565-73. PubMed ID: 9437800
[TBL] [Abstract][Full Text] [Related]
26. NF2 alteration in mesothelioma.
Sekido Y; Sato T
Front Toxicol; 2023; 5():1161995. PubMed ID: 37180489
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene.
Deguen B; Goutebroze L; Giovannini M; Boisson C; van der Neut R; Jaurand MC; Thomas G
Int J Cancer; 1998 Aug; 77(4):554-60. PubMed ID: 9679758
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
Baser ME; Rai H; Wallace AJ; Evans DG
Fam Cancer; 2005; 4(4):321-2. PubMed ID: 16341811
[TBL] [Abstract][Full Text] [Related]
29. Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells.
Utermark T; Alekov A; Lerche H; Abramowski V; Giovannini M; Hanemann CO
Cancer; 2003 Apr; 97(8):1955-62. PubMed ID: 12673723
[TBL] [Abstract][Full Text] [Related]
30. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO).
Dopp E; Poser I; Papp T
Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL271-7. PubMed ID: 12643444
[TBL] [Abstract][Full Text] [Related]
31. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.
Shukla A; Barrett TF; MacPherson MB; Hillegass JM; Fukagawa NK; Swain WA; O'Byrne KJ; Testa JR; Pass HI; Faux SP; Mossman BT
Am J Respir Cell Mol Biol; 2011 Nov; 45(5):906-14. PubMed ID: 21454801
[TBL] [Abstract][Full Text] [Related]
32. Circulating long non-coding RNA
Weber DG; Casjens S; Brik A; Raiko I; Lehnert M; Taeger D; Gleichenhagen J; Kollmeier J; Bauer TT; Brüning T; Johnen G;
Biomark Res; 2020; 8():15. PubMed ID: 32435497
[TBL] [Abstract][Full Text] [Related]
33. Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.
Kadariya Y; Menges CW; Talarchek J; Cai KQ; Klein-Szanto AJ; Pietrofesa RA; Christofidou-Solomidou M; Cheung M; Mossman BT; Shukla A; Testa JR
Cancer Prev Res (Phila); 2016 May; 9(5):406-414. PubMed ID: 26935421
[TBL] [Abstract][Full Text] [Related]
34. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Xu J; Kadariya Y; Cheung M; Pei J; Talarchek J; Sementino E; Tan Y; Menges CW; Cai KQ; Litwin S; Peng H; Karar J; Rauscher FJ; Testa JR
Cancer Res; 2014 Aug; 74(16):4388-97. PubMed ID: 24928783
[TBL] [Abstract][Full Text] [Related]
35. Functional inactivation of NF2/merlin in human mesothelioma.
Thurneysen C; Opitz I; Kurtz S; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2009 May; 64(2):140-7. PubMed ID: 18835652
[TBL] [Abstract][Full Text] [Related]
36. Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Kachali C; Eltoum I; Horton D; Chhieng DC
Semin Diagn Pathol; 2006 Feb; 23(1):20-4. PubMed ID: 17044192
[TBL] [Abstract][Full Text] [Related]
37. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
[TBL] [Abstract][Full Text] [Related]
38. A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells.
Häner K; Henzi T; Pfefferli M; Künzli E; Salicio V; Schwaller B
J Cell Biochem; 2010 Feb; 109(3):519-31. PubMed ID: 19998412
[TBL] [Abstract][Full Text] [Related]
39. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo characterization of highly purified human mesothelioma derived cells.
Melotti A; Daga A; Marubbi D; Zunino A; Mutti L; Corte G
BMC Cancer; 2010 Feb; 10():54. PubMed ID: 20175889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
